Launching a Biological Drug in China: From Biosimilar to Innovative Molecules Key Consideration for mAb and Biological Therapeutics

Posted on July 5, 2018

Joe X Zhou, Ph.D., CEO
Genor BioPharma
Jinhai Shi, Ph.D., General Secretary
China Protein Drug Quality Alliance

Global: Continuous Growing Trend of Biologics The global market of monoclonal antibody therapeutics (mAb) reached around $62.3bn (USD) in 2015, up from $44.6bn in 2010 due to many blockbuster mAb therapeutics approved. It definitely demonstrated that mAb therapeutics are the leading sector among all...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy

Related Topics and Keywords

, , , , , ,

Related Products


Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy